Background
==========

Iodinated contrast media (ICM) have found widespread use in diagnostic imaging and therapeutic procedures. Despite their generally high safety profile, possibility or adverse reactions should be taken into account every time they are used. The reactions may range from transient, mild allergic reactions to acute, directly life-threatening conditions.

It appears that the most important clinical challenge associated with the use of ICM is their potential nephrotoxicity. This includes both acute and delayed renal complications. Despite various controversies, most researchers agree that contrast-induced nephropathy (CIN) is of the highest clinical importance. It worsens the short-term (increased frequency of hospitalizations, dialysis, in-hospital mortality) as well as long-term prognoses for patients \[[@b1-poljradiol-81-157],[@b2-poljradiol-81-157]\]. The objective of this study is to present the literature data on the safety of contrast media used in radiodiagnostics with particular focus on the differences in the presented opinions as discrepancies in positions on the safety of individual contrast media is of particular importance and requires special attention, particularly in terms of assessing the population sizes and methods used in the meta-analyses.

Non-Renal Adverse Reactions
===========================

The adverse reactions following the administration of contrast media may be classified as immediate or delayed. Most common (\<3%) are immediate mild reactions such as nausea, vomiting, urticaria, pruritus, or cough \[[@b3-poljradiol-81-157]\]. Moderate and severe immediate adverse reactions are much less common (\<0.04%). These include facial edema, laryngeal edema, bronchospasm, bradycardia, tachycardia, arrhythmias, hyper- or hypotension, coronary artery spasm, pulmonary edema, loss of consciousness or conditions requiring immediate treatment \[[@b3-poljradiol-81-157]\]. Death is a very rare consequence, its incidence being estimated at 1 per 1 million cases \[[@b3-poljradiol-81-157]\]. The reactions may develop along IgE-dependent or IgE-independent hypersensitivity mechanism \[[@b3-poljradiol-81-157]\].

Delayed adverse reactions are defined as occurring within the time frame between 1 hour and 1 week after administration of the contract medium. In most cases, these include skin reactions such as rash, erythema, or pruritus. The incidence of these reactions is difficult to establish (1--25% according to various sources). In author's opinion, part of the reported reactions may be mistakenly associated with the contrast medium while being due to a completely different causal factor. Most reactions of this type are mild or moderate and resolve spontaneously. In practice, delayed reactions occur after the patient leaves the diagnostic lab. The mechanism of delayed skin reactions is not fully understood, being probably associated with cellular hypersensitivity reactions involving T lymphocytes \[[@b4-poljradiol-81-157]\].

An additional class consists of very late adverse reactions that occur later than 1 week after contract administration. In nearly all cases, they are associated with the thyroid function being disturbed after administration of the contrast medium. Biological effects of iodine contained within the contrast medium may consist in either hypo- or hyperthyroidism. High-risk groups include patients with untreated Graves' disease, patients with multinodular goiter and thyroid autonomy, particularly elderly patients and/or residents of areas characterized by iodine-deficient diets \[[@b3-poljradiol-81-157]\]. Patients with Hashimoto disease or patients after partial thyroidectomy are at a higher risk of radiocontrast-induced thyroid dysfunction \[[@b5-poljradiol-81-157]\].

Systemic effects may ensue following the administration of the contrast medium into the vascular system. The impact on the morphology (shape, plasticity) of erythrocytes is most probably due to the chemotoxic and dehydrating effects and may lead to disturbed microcirculation \[[@b6-poljradiol-81-157],[@b7-poljradiol-81-157]\]. The process may be enhanced by interactions between the contrast medium with capillary endothelial cells \[[@b8-poljradiol-81-157]\]. The integrity of vascular endothelium may be compromised due to the deformation of endothelial cells and breakage of intercellular bridges leading to exposure of extracellular matrix \[[@b8-poljradiol-81-157]\].

Renal Adverse Reactions
=======================

Contrast induced nephropathy (CIN) is an acute renal insufficiency in a patient with normal renal function preceding the diagnostic procedure involving contrast administration or a significant worsening of renal function in patients previously diagnosed with chronic renal insufficiency. According to ESUR, significant worsening of renal function is determined on the basis of laboratory standards including creatinine clearance reduced by ≥25% or serum creatinine levels increased by ≥25% or ≥0.5 mg/dL (44.2 μmol/L) compared to the values before the procedure (within 3 days after contrast administration). The actual incidence of contrast-enhanced nephropathy is difficult to establish as it depends on the definition of CIN, the type of medical procedure, the route of contrast administration, differences in the distribution of risk factors in the study population and the methodology of assessment of renal parameters during the follow-up. Due to the number of variables being this high, literature reports differ in their estimations of the scale of the problem. Studies conducted in large populations of patients after intravenous administration of contrast media revealed acute worsening of renal function in 2.5--12% of patients \[[@b9-poljradiol-81-157],[@b10-poljradiol-81-157]\]. Higher incidence of CIN, ranging from 7 to 50%, was observed in studies in which both the intravenous and the intraarterial route were taken into consideration \[[@b11-poljradiol-81-157],[@b12-poljradiol-81-157]\]. The morbidity in the overall population of unburdened patients is below 2% \[[@b13-poljradiol-81-157]\]. The risk of CIN is significantly higher in patients of the high risk groups ([Table 1](#t1-poljradiol-81-157){ref-type="table"}), particularly in patients with comorbid diabetes \[[@b14-poljradiol-81-157]\]. Despite the many years of experience in the use of iodinated contrast media, the exact pathogenesis of contrast-induced nephropathy remains unknown. Numerous clinical studies are conducted to examine the impact of the molarity of the active substances on the renal function. The osmotic effect of contrast media on the kidneys involves increased release of sodium and water as well as a reduction in three parameters, namely renal blood flow (RBF), glomerular filtration rate (GFR), as well as filtration fraction (FF) \[[@b13-poljradiol-81-157]\]. Other factors that impair the renal blood flow include increased levels of vasoconstrictive factors such as adenosine or endothelin with simultaneous drop in the levels of vasodilators such as nitric oxide or prostacyclin \[[@b14-poljradiol-81-157]\]. Simultaneously, the toxic effect of contrast molecules on renal tubules exerted by means of reactive oxygen species is being highlighted \[[@b15-poljradiol-81-157],[@b16-poljradiol-81-157]\].

Classification of Iodinated Contrast Media
==========================================

The iodinated contrast media available at the market consist of one (monomers) or two (dimers) triiodinated benzene rings. Contrast media are divided into three basic groups according to their osmolarity (the number of moles of the active substance dissolved in 1 kilogram of water) \[[@b15-poljradiol-81-157]\]. The oldest substances, referred to as high-osmolar contrast media (HOCM) are characterized by osmolarity of above 1500 mOsm/kg H~2~O and are currently not recommended for intravascular use due to the high risk of adverse reactions. Low osmolar contrast media (LOCM) are characterized by osmolarities within a relatively wide range of 300--900 mOsm/kg H~2~O, and are thus a heterogeneous group of compounds with different physicochemical parameters. These include iobitridol, iohexol, iomeprol, iopamidol, iopromide, ioversol, ioxaglate and ioxilan. The third group of iso-osmolar contrast media (IOCM) consists of iodixanol as the only member or the group. It is characterized by osmolarity level similar to that of blood (290 mOsm/kg H~2~O) and dimeric and dimeric structure as opposed to monomeric HOCM and LOCM (except for ioxaglate which is an LOCM of a dimeric structure).

Analysis of Clinical Studies -- Intraarterial Administration
============================================================

Intraarterial administration is associated with the highest risk of adverse reactions. Clinical studies listed below (positions 17--31, [Tables 2](#t2-poljradiol-81-157){ref-type="table"}, [3](#t3-poljradiol-81-157){ref-type="table"}) directly compared the iso-osmolar medium (dimer) with low-osmolar media (monomers) in terms of the incidence of contrast-induced nephropathy. Overall, 4621 patients were enrolled into 15 analyzed clinical studies. Low-osmolar contract media were administered to 2322 patients (iopamidol n=572; iopromide n=924; iomeprol n=162; iohexol n=65; iobitridol n=115; ioversol n=275;ioxaglate n=209), while the iso-osmolar contrast medium (iodixanol) was used in 2299 cases.

Four clinical studies (NEPHRIC, RECOVER, Hernandez et al., Nie et al.) conducted in 862 patients and comparing iso-osmolar iodixanol with low-osmolarity media (iohexol, ioxaglate, iopromide, ioversol) demonstrated a statistically significantly lower incidence of CIN complications following the administration of the former. The remaining 11 studies (3759 patients -- iodixanol *vs.* iopamidol, iopromide, iomeprol, ioversol, ioxaglate) revealed no statistically significant differences in study endpoints or were suggestive of higher safety of LOCM.

Analysis of Clinical Studies -- Intravenous Administration
==========================================================

This section deals with clinical studies (positions 32--38; [Tables 4](#t4-poljradiol-81-157){ref-type="table"}, [5](#t5-poljradiol-81-157){ref-type="table"}) that assessed the incidence of CIN following intravenous administration of iso-osmolar contrast medium compared to low-osmolarity media ([Tables 4](#t4-poljradiol-81-157){ref-type="table"}, [5](#t5-poljradiol-81-157){ref-type="table"}). A total of 7 clinical studies with the total number of 925 patients were analyzed. Low-osmolar contrast media were administered to 465 patients (iopamidol n=202; iopromide n=88; iomeprol n=76; iohexol n=25; iobitridol n=74), while the iso-osmolar contrast medium (iodixanol) was used in 460 cases. One of the analyzed studies, conducted in 117 patients (Nguyen et al; iodixanol n=61 *vs.* iopromide n=56) revealed a lower number of CIN cases following administration of IOCM. The remaining 6 studies conducted in the overall population of 808 patients revealed no superiority of iso-osmolar medium (iodixanol) or were suggestive of the superiority of low-osmolar contrast media (iopamidol, iopromide, iomeprol, iohexol, iobitridol).

Meta-Analysis, Summary Reports
==============================

This section presents summary reports of multiple studies (positions 39--47; [Table 6](#t6-poljradiol-81-157){ref-type="table"}). When analyzing the presented data, one should consider the lack of unanimous definition of CIN, differences in patient groups and different types of studies. It is therefore difficult to draw explicit conclusions; however, the data reveal some important, mutually confirming correlations. Of much importance are the study endpoints including the incidence of CIN. The higher the incidence, the less safe the contrast medium.

The results of metaanalyses are suggestive of a very important hypothesis, according to which low-osmolarity contrast media (LOCM) are not a homogeneous group of compounds. Of note are the repeatedly poorer results for iohexol and ioxaglate as compared to the remaining LOCM. The data support the thesis regarding the benefits of iodixanol (IOCM) as compared to particular agents from the LOCM group such as iohexol and ioxaglate while not confirming the superiority of iodixanol over other low-osmolarity media.

Conclusions
===========

The discussion on the safety of contrast media and the clinical importance of their individual properties is far from being closed. Each new study is a source of new data. Due to the non-homogeneous patient groups, differences in the definitions of CIN as well as differences in the study methodologies assumed by the authors, it is difficult to carry out a comparative analysis of individual products. Careful analysis of the results published in recent years suggests high degree of arbitrariness in the choice of methodologies, potentially leading to low conformity of data and formulation of false conclusions. Taking these limitations into consideration, one may conclude that despite the lower osmolarity of the dimeric medium, clinical practice and, most of all, the results of randomized studies confirm the comparably high level of safety as regards nephrotoxicity of the iso-osmolar medium and most low-osmolar media, which is reflected in current guidelines proposed by competent scientific associations ([Table 7](#t7-poljradiol-81-157){ref-type="table"}). This conclusion pertains to both intravenous and intraarterial administration. At the same time, low-osmolarity contrast media should not be considered a homogeneous group.

In case of high-risk patients, on the basis of the currently available literature data, all contrast media, including the iso-osmolar dimer, iodixanol, may be potentially nephrotoxic and relying on a particular agent with the purpose of reducing the risk of CIN may be deceptive. The safest way to minimize the risk of CIN is to use the possibly lowest dose of a low- or iso-osmolar contrast medium while ensuring appropriate hydration.

###### 

Risk factors of CIN according to the European Society of Urogenital Radiology.

  Risk factors of CIN according to the European Society of Urogenital Radiology
  --------------------------------------------------------------------------------
  eGFR \<60 mL/min/1.73 m^2^ before arterial administration of a contrast medium
  eGFR \<45 mL/min/1.73 m^2^ before venous administration of a contrast medium
  Diabetic nephropathy
  Dehydration
  Congestive heart failure (NYHA III and IV)
  History of heart attack (\<24 h)
  Use of nephrotoxic drugs
  Age \>70
  High dose of a contrast medium

###### 

Study list and details -- intraarterial administration.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                       Patient population               Endpoints/definition of CIN                                     Study type                               Sponsor                    Procedure        Statistical sample power
  ------------------------------------------------- -------------------------------- --------------------------------------------------------------- ---------------------------------------- -------------------------- ---------------- --------------------------
  Aspelin et al. \[[@b17-poljradiol-81-157]\]       Patients with CRI and diabetes   SCr ≥0.5 mg/dL 72 h after administration                        Prospective, randomized Double-blinded   GEHC                       PCI 42 CXA 126   80%\
                                                                                                                                                                                                                                          N=129

  Briguori et al. \[[@b18-poljradiol-81-157]\]      Patients with CRI                SCr ≥0.5 mg/dL 48 h after administration                        Retrospective                            Investigator               PCI 101\         Not available\
                                                                                                                                                                                                                         CXA 102          N=225

  Jo et al. \[[@b19-poljradiol-81-157]\]            Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Prospective, randomized Double-blinded   Investigator               PCI 113\         80%\
                                                                                                                                                                                                                         CXA 162          N=275

  Rudnick et al. \[[@b20-poljradiol-81-157]\]       Patients with CRI                SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Prospective, randomized Double-blinded   GEHC                       PCI\             90%\
                                                                                                                                                                                                                         CXA              N=299

  Ni et al. \[[@b21-poljradiol-81-157]\]            Patients with CRI                SCr ≥25% 24 h after administration                                                                       Investigator               PCI              Not available\
                                                                                                                                                                                                                                          N=285

  Hérnandez F et al. \[[@b22-poljradiol-81-157]\]   Patients with diabetes           SCr ≥0.5 mg/dL and/or SCr ≥25% 72 h after administration        Prospective, not randomized              Investigator               PCI 102\         Not available\
                                                                                                                                                                                                                         CXA 148          N=250

  Solomon et al. \[[@b23-poljradiol-81-157]\]       Patients with CRI                SCr ≥0.5 mg/dL 48--72 h after administration                    Prospective, randomized Double-blinded   Bracco                     PCI 163\         80%\
                                                                                                                                                                                                                         CXA 251          N=414

  Nie et al. \[[@b24-poljradiol-81-157]\]           Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Prospective, randomized Double-blinded   Investigator               PCI 98\          80%\
                                                                                                                                                                                                                         CXA 110          N=208

  Wessely et al. \[[@b25-poljradiol-81-157]\]       Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Prospective, randomized Double-blinded   GEHC                       PCI              90%\
                                                                                                                                                                                                                                          N=324

  Mehran et al. \[[@b26-poljradiol-81-157]\]        Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Prospective, randomized Double-blinded   Mallinckrodt and Guerbet   PCI 96\          80%\
                                                                                                                                                                                                                         CXA 50           N=146

  Laskey et al. \[[@b27-poljradiol-81-157]\]        Patients with CRI and diabetes   SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Prospective, randomized Double-blinded   GEHC                       PCI 109\         90%\
                                                                                                                                                                                                                         CXA 309          N=418

  Shin et al. \[[@b28-poljradiol-81-157]\]          Patients with CRI                SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Prospective, randomized Double-blinded   Investigator               PCI 189\         80%\
                                                                                                                                                                                                                         CXA 231          N=420

  Bolognese et al. \[[@b29-poljradiol-81-157]\]     Patients with CRI                SCr ≥25% 72 h after administration                              Prospective, randomized Single-blinded   Bayer Schering             PCI              8%\
                                                                                                                                                                                                                                          N=475

  Juergens et al. \[[@b30-poljradiol-81-157]\]      Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 48 h after administration        Prospective, randomized Double-blinded   Investigator               CXA 156\         80%\
                                                                                                                                                                                                                         PCI 35           N=191

  Chen et al. \[[@b31-poljradiol-81-157]\]          Patients with CRI                SCr ≥50% 72 h after administration                              Prospective, randomized Double-blinded   Bayer HC                   CXA 307\         80%\
                                                                                                                                                                                                                         PCI 255          N=592
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Analysis of the results of studies listed in [Table 2](#t2-poljradiol-81-157){ref-type="table"}.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                     Patient population               Endpoints/definition of CIN                                     Contrast media             Results
  ----------------------------------------------- -------------------------------- --------------------------------------------------------------- -------------------------- ----------------------------------------------------------------------
  Aspelin et al. \[[@b17-poljradiol-81-157]\]     Patients with CRI and diabetes   SCr ≥0.5 mg/dL 72 h after administration                        Iodixanol 320 (N=64)\      Iohexol \>Iodixanol (26% *vs.* 3%, p \< 0.05)
                                                                                                                                                   Iohexol 350 (N=65)         

  Briguori et al. \[[@b18-poljradiol-81-157]\]    Patients with CRI                SCr ≥0.5 mg/dL 48 h after administration                        Iodixanol 320 (N=110)\     No significant difference (Iodixanol 3%, Iobitridol 4%, p=n.s.)
                                                                                                                                                   Iobitridol 350\* (N=115)   

  Jo et al. \[[@b19-poljradiol-81-157]\]          Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Iodixanol 320 (N=140)\     Ioxaglate \> Iodixanol (17% *vs.* 8%, p\<0.05)
                                                                                                                                                   Ioxaglate 320 (N=135)      

  Rudnick et al. \[[@b20-poljradiol-81-157]\]     Patients with CRI                SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Iodixanol 320 (N=156)\     No significant difference (Iodixanol 22%, Ioversol 24%, p=n.s.)
                                                                                                                                                   Ioversol 320 (N=143)       

  Ni et al. \[[@b21-poljradiol-81-157]\]          Patients with CRI                SCr ≥25% 24 h after administration                              Iodixanol (N=120)\         No significant difference (Iodixanol 11.7%, Iopamidol 19.4%, p=n.s.)
                                                                                                                                                   Iopamidol (N=165)          

  Hérnandez et al. \[[@b22-poljradiol-81-157]\]   Patients with diabetes           SCr ≥0.5 mg/dL and/or SCr ≥25% 72 h after administration        Iodixanol (N=118)\         Ioversol \> Iodixanol (8.3% *vs.* 2.5%, p\<0.05)
                                                                                                                                                   Ioversol (N=132)           

  Solomon et al. \[[@b23-poljradiol-81-157]\]     Patients with CRI                SCr ≥0.5 mg/dL 48--72 h after administration                    Iodixanol 320 (N=210)\     No significant difference (Iodixanol 7%, Iopamidol 4%, p=n.s.)
                                                                                                                                                   Iopamidol 370 (N=204)      

  Nie et al. \[[@b24-poljradiol-81-157]\]         Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Iodixanol 320 (N=106)\     Iopromide \>Iodixanol (16.7% *vs.* 5.7%, p\<0.01.)
                                                                                                                                                   Iopromide 370 (N=102)      

  Wessely et al. \[[@b25-poljradiol-81-157]\]     Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Iodixanol 320 (N=162)\     No significant difference (Iodixanol 22.2%, Iomeprol 27.7%, p=n.s.)
                                                                                                                                                   Iomeprol 350 (N=162)       

  Mehran et al. \[[@b26-poljradiol-81-157]\]      Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 1--2 days after administration   Iodixanol 320 (N=72)\      No significant difference (Iodixanol 15.9%, Ioxaglate 24.2%, p=n.s.)
                                                                                                                                                   Ioxaglate 320 (N=74)       

  Laskey et al. \[[@b27-poljradiol-81-157]\]      Patients with CRI and diabetes   SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Iodixanol 320 (N=215)\     No significant difference (Iodixanol 11%, Iopamidol 9%, p=n.s.)
                                                                                                                                                   Iopamidol 370 (N=203)      

  Shin et al. \[[@b28-poljradiol-81-157]\]        Patients with CRI                SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Iodixanol 320 (N=215)\     No significant difference (Iodixanol 10.7%, Iopromide 7.8%, p=n.s.)
                                                                                                                                                   Iopromide 300 (N=205)      

  Bolognese et al. \[[@b29-poljradiol-81-157]\]   Patients with CRI                SCr ≥25% 72 h after administration                              Iodixanol 320 (N=236)\     No significant difference (Iodixanol 13%, Iopromide 10%, p=n.s.)
                                                                                                                                                   Iopromide 370 (N=239)      

  Juergens et al. \[[@b30-poljradiol-81-157]\]    Patients with CRI                SCr ≥0.5 mg/dL and/or SCr ≥25% 48 h after administration        Iodixanol 320 (N=91)\      No significant difference (Iodixanol 12%, Iopromide 15%, p=n.s.)
                                                                                                                                                   Iopromide 370 (N=100)      

  Chen et al. \[[@b31-poljradiol-81-157]\]        Patients with CRI                SCr ≥50% 72 h after administration                              Iodixanol 320 (N=284)\     No significant difference (Iodixanol 0.3%, Iopromide 0.4%, p=n.s.)
                                                                                                                                                   Iopromide 370 (N=278)      
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Study list and details -- intravenous administration.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                   Patient population                                           Endpoints/definition of CIN                                     Study type                               Sponsor        Procedure        Statistical sample power
  --------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------- ---------------------------------------- -------------- ---------------- --------------------------
  Carraro et al. \[[@b32-poljradiol-81-157]\]   Patients with mild to moderate CRI                           SCr ≥50% 24 h after administration                              Prospective, randomized Double-blinded   Investigator   i.v. urography   80%\
                                                                                                                                                                                                                                                      N=64

  Chuang et al. \[[@b33-poljradiol-81-157]\]    Patients with CRI and/or diabetes                            SCr ≥25% 72 h after administration                              Prospective, randomized Double-blinded   Investigator   i.v. urography   Not available\
                                                                                                                                                                                                                                                      N=50

  Barrett et al. \[[@b34-poljradiol-81-157]\]   Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL and/or SCr ≥25% 2--2 days after administration   Prospective, randomized Double-blinded   Bracco         CT               Not available\
                                                                                                                                                                                                                                                      N=153

  Thomsen et al. \[[@b35-poljradiol-81-157]\]   Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL 24, 48 amd 72 h after administration             Prospective, randomized Double-blinded   Bracco         CT               Not available\
                                                                                                                                                                                                                                                      N=184

  Nguyen et al. \[[@b36-poljradiol-81-157]\]    Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL 24, 48 and 72 h after administration             Prospective, randomized Double-blinded   GEHC           CT               95%\
                                                                                                                                                                                                                                                      N=117

  Kuhn et al. \[[@b37-poljradiol-81-157]\]      Patients with moderate to severe CRI                         SCr ≥25% 48--72 h after administration                          Prospective, randomized Double-blinded   Bracco         CT               Not available\
                                                                                                                                                                                                                                                      N=248

  Zo'o et al. \[[@b38-poljradiol-81-157]\]      Pediatric patients (aged 1--16) with normal renal function   SCr ≥0.5 mg/dL 48--72 h after administration                    Prospective, randomized Double-blinded   Guerbet        CT               80%\
                                                                                                                                                                                                                                                      N=146
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Analysis of the results of studies listed in [Table 4](#t4-poljradiol-81-157){ref-type="table"}.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                   Patient population                                           Endpoints/definition of CIN                           Contrast media           Results
  --------------------------------------------- ------------------------------------------------------------ ----------------------------------------------------- ------------------------ --------------------------------------------------------------------------------------
  Carraro et al. \[[@b32-poljradiol-81-157]\]   Patients with mild to moderate CRI                           SCr ≥50% 24 h after administration                    Iodixanol 320 (N=32)\    No significant difference
                                                                                                                                                                   Iopromide 300 (N=32)     

  Chuang et al. \[[@b33-poljradiol-81-157]\]    Patients with CRI and/or diabetes                            SCr ≥25% 72 h after administration                    Iodixanol\* (N=25)\      No significant difference
                                                                                                                                                                   Iohexol\* (N=25)\        
                                                                                                                                                                   \*mgI/mL not available   

  Barrett et al. \[[@b34-poljradiol-81-157]\]   Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL 48--72 h after administration          Iodixanol 320 (N=76)\    No significant difference (2.6% *vs.* 0, p=0.3)
                                                                                                                                                                   Iopamidol 370 (N=77)\    
                                                                                                                                                                   Dose: 40 g I             

  Thomsen et al. \[[@b35-poljradiol-81-157]\]   Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL 48--72 h after administration          Iodixanol 320 (N=72)\    Ioversol \> Iomeprol (6.9% *vs.* 2.5%, p \< 0.03)
                                                                                                                                                                   Iomeprol 400 (N=76)\     
                                                                                                                                                                   Dose: 40 g I             

  Nguyen et al. \[[@b36-poljradiol-81-157]\]    Patients with moderate to severe CRI                         SCr ≥0.5 mg/dL 24, 48 and 72 h after administration   Iodixanol 320 (N=61)\    Iohexol \> Iopromide (5.1% *vs.* 18.6%, p\<0.04)
                                                                                                                                                                   Iopromide 370 (N=56)\    
                                                                                                                                                                   Dose: 37 g I             

  Kuhn et al. \[[@b37-poljradiol-81-157]\]      Patients with moderate to severe CRI                         SCr ≥25% 48--72 h after administration                Iodixanol 320 (N=123)\   No significant difference (4.9% *vs.* 5.6, p=1.0)
                                                                                                                                                                   Iopamiron 370 (N=125)\   
                                                                                                                                                                   Dose:\                   
                                                                                                                                                                   Iodixanol 32.5 g I\      
                                                                                                                                                                   Iopamidol 39.4 g I       

  Zo'o et al. \[[@b38-poljradiol-81-157]\]      Pediatric patients (aged 1--16) with normal renal function   SCr ≥0.5 mg/dL 48--72 h after administration          Iodixanol 270 (N=71)\    No significant difference (ITT 10.6% *vs.* 4.8%, p=0.72.) PP 10.3% *vs.* 0%, p=0.68)
                                                                                                                                                                   Iobitridol 300 (N=74)    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Meta-analyses.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Publication                                          Patient population                              Endpoints/definition of CIN                                        Contrast media                                                                                                                                                         Results
  ---------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  McCullough et al. \[[@b39-poljradiol-81-157]\]       Patients with normal renal function (N=3,008)   SCr ≥0.5 mg/dL 18 h -- 7 days after administration                 Iodixanol 320 (N=1,382)Ioxaglate (N=789)Iohexol (N=381)Iopromide (N=106)Iopamidol (N=69)                                                                               Iohexol and Ioxaglate \> Iodixanol

  Sharma et al. \[[@b40-poljradiol-81-157]\]           Patients with CRI(N=560)                        SCr ≥0.5 mg/dL and/or SCr ≥25% 48--72 hours after administration   Iodixanol 320 (N=209)Iohexol (N=106)Iopamidol (N=245)                                                                                                                  Iohexol \> IodixanolIohexol \> IopamidolIopamidol = Iodixanol

  Solomon \[[@b41-poljradiol-81-157]\]                 Patients with CRI (N=1,365)                     SCr ≥0.5 mg/dL and/or SCr ≥25% 1--7 days after administration      Iodixanol 320 (N=263)Iohexol (N=431)Iopamidol (N=400)Other LOCM (N=271)                                                                                                Iohexol \> IodixanolIohexol \> IopamidolIopamidol = Iodixanol

  Solomon and DuMouchel \[[@b42-poljradiol-81-157]\]   Patients with CRI(N=3.112)                      SCr ≥0.5 mg/dL and/or SCr ≥25% 1--7 days after administration      Iodixanol 320 (N=569)Iohexol (N=677)Iopamidol (N=652)Ioversol (N=447)Other LOCM (N=767)                                                                                Iohexol \> IodixanolIohexol \> IopamidolIohexol = IoversolIopamidol = Visipaque

  Heinrich et al. \[[@b43-poljradiol-81-157]\]         3,270 patients                                  25 randomized studies\                                             Iodixanol (N=1,701)LOCM (N=1,569)                                                                                                                                      Iohexol \> Iodixanol after i.a. administrationNo difference with LOCM other than iohexol
                                                                                                       Administration route: 17 i.a. / 8 i.v.                                                                                                                                                                                                    

  Reed et al. \[[@b44-poljradiol-81-157]\]             2,763 patientsów                                16 randomized studies\                                             Iodixanol (N=1383)Ioversol (N=1380)                                                                                                                                    Iohexol and Ioxaglate \> IodixanolNo difference with LOCM other than iohexol and ioxaglate
                                                                                                       Administration route: 11 i.a. / 5 i.v.                                                                                                                                                                                                    

  From et al. \[[@b45-poljradiol-81-157]\]             7,166 patients                                  36 randomized studies\                                             Iodixanol (N=3672)LOCM (N=3494)                                                                                                                                        Iohexol \> IodixanolNo superiority of IOCM as compared LOCM other than iohexol
                                                                                                       1966--2009\                                                                                                                                                                                                                               
                                                                                                       Administration route: 27 i.a. / 9 i.v.                                                                                                                                                                                                    

  Dong et al. \[[@b46-poljradiol-81-157]\]             3,129 patients                                  18 randomized studies\                                             Iodixanol (N=1604)LOCM (N=1525)                                                                                                                                        Iodixanol \> LOCM after i.a. administration
                                                                                                       Administration route: 11 i.a. / 7 i.v.                                                                                                                                                                                                    

  Biondi-Zoccai et al. \[[@b47-poljradiol-81-157]\]    10,048 patients                                 42 randomized studies\                                             Iodixanol *vs.* Iohexol (N=982)Iodixanol *vs.* Iopromide (N= 2202)Iodixanol *vs.* Iomeron (N=1667)Iodixanol *vs.* Ioxaglate (N=2826)Iodixanol *vs.* Ioversol (N=334)   Iohexol \> IodixanolIopamidol, Iomeprol, Ioversol and Iodixanol had similar safety profilesFurther studies are required for Iopromide
                                                                                                       Administration route: 32 i.a. / 10 i.v.                                                                                                                                                                                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Guidelines of scientific associations.

  Scientific association                                                                                                                      Recommendations
  ------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  American College of Radiology \[[@b48-poljradiol-81-157]\]                                                                                  "Studies \[...\] revealed no evident superiority of iso-osmolar iodixanol over low-osmolar contrast media with respect to the incidence of CIN A meta-analysis conducted in 2009 on cumulative data of 25 clinical trials revealed no difference in the incidence of CIN between iodixanol and low-osmolar contract media following intravenouis administration \[...\]"
  ESUR Contrast Media Safety Committee \[[@b49-poljradiol-81-157]\]                                                                           "The previous recommendations \[of the Safety Committee\] proposed that low-osmolar or iso-osmolar contrast media be used in patients with CIN risk factors. Having considered numerous studies published in recent years, the Committee found no grounds for changing this position"
  Canadian Association of Radiologists \[[@b50-poljradiol-81-157]\]                                                                           "Larger studies and meta-analyses revealed no significant difference between iodixanol and most low-osmolar contrast media. \[...\] Currently, the Canadian Associstion of Radiologists recommends the use of iso- or low-osmolar contrast media in patients with GFR \<45 mL/ min in intravenous administration and GFR \<60 mL/min at intraarterial administration"
  The Renal Association, British Cardiovascular and Intervention Society and The Royal College of Radiologists \[[@b51-poljradiol-81-157]\]   "We are suggesting that a lowest possible volume of a low- or iso-osmolar contrast medium is used in patients with risk factors of acute contrast-induced nephropwthy."
  American College of Cardiology Foundation/Society for Cardiovascular Angiography and Interventions \[[@b52-poljradiol-81-157]\]             "\[The volume of\] contrast media should be minimized, and low-osmolar or iso-osmolar contrast media should be used"
  European Society of Cardiology \[[@b53-poljradiol-81-157]\]                                                                                 "In patients with mild, moderate or severe chronic renal insufficiency, low-osmolar or iso-osmolar contrast media are recommended at doses of \<350 mL or 4 mL/kg \[of body weight\]"
  Asian Society of Cardiovascular Imaging \[[@b54-poljradiol-81-157]\]                                                                        "Low- or iso-osmolar contrast media are recommended"
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